Basit öğe kaydını göster

dc.contributor.authorPaladino, Andrew J.
dc.contributor.authorPebley, Kinsey
dc.contributor.authorKoçak, Mehmet
dc.contributor.authorKrukowski, Rebecca A.
dc.contributor.authorWaters, Teresa M.
dc.contributor.authorVidal, Gregory
dc.contributor.authorSchwartzberg, Lee S.
dc.contributor.authorCurry, Andrea N.
dc.contributor.authorGraetz, Ilana
dc.date.accessioned2022-12-02T08:13:43Z
dc.date.available2022-12-02T08:13:43Z
dc.date.issued2022en_US
dc.identifier.citationPaladino, A. J., Pebley, K., Koçak, M., Krukowski, R. A., Waters, T. M., Vidal, G. ... Graetz, I. (2022). An examination of health care utilization during the COVID-19 pandemic among women with early-stage hormone receptor-positive breast cancer. BMC Health Services Research, 22(1). https://doi.org/10.1186/s12913-022-08705-9en_US
dc.identifier.issn1472-6963
dc.identifier.urihttps://doi.org/10.1186/s12913-022-08705-9
dc.identifier.urihttps://hdl.handle.net/20.500.12511/10063
dc.description.abstractBackground: Women undergoing treatment for breast cancer require frequent clinic visits for maintenance of therapy. With COVID-19 causing health care disruptions, it is important to learn about how this population’s access to health care has changed. This study compares self-reported health care utilization and changes in factors related to health care access among women treated at a cancer center in the mid-South US before and during the pandemic. Methods: Participants (N = 306) part of a longitudinal study to improve adjuvant endocrine therapy (AET) adherence completed pre-intervention baseline surveys about their health care utilization prior to AET initiation. Questions about the impact of COVID-19 were added after the pandemic started assessing financial loss and factors related to care. Participants were categorized into three time periods based on the survey completion date: (1) pre-COVID (December 2018 to March 2020), (2) early COVID (April 2020 – December 2020), and later COVID (January 2021 to June 2021). Negative binomial regression analyses used to compare health care utilization at different phases of the pandemic controlling for patient characteristics. Results: Adjusted analyses indicated office visits declined from pre-COVID, with an adjusted average of 17.7 visits, to 12.1 visits during the early COVID period (p = 0.01) and 9.9 visits during the later COVID period (p < 0.01). Hospitalizations declined from an adjusted average 0.45 admissions during early COVID to 0.21 during later COVID, after vaccines became available (p = 0.05). Among COVID period participants, the proportion reporting changes/gaps in health insurance coverage increased from 9.5% participants during early-COVID to 14.8% in the later-COVID period (p = 0.05). The proportion reporting financial loss due to the pandemic was similar during both COVID periods (34.3% early- and 37.7% later-COVID, p = 0.72). The proportion of participants reporting delaying care or refilling prescriptions decreased from 15.2% in early-COVID to 4.9% in the later-COVID period (p = 0.04). Conclusion: COVID-19 caused disruptions to routine health care for women with breast cancer. Patients reported having fewer office visits at the start of the pandemic that continued to decrease even after vaccines were available. Fewer patients reported delaying in-person care as the pandemic progressed.en_US
dc.description.sponsorshipNational Cancer Institute ; Division of Cancer Prevention, National Cancer Institute ; Center for Strategic Scientific Initiatives, National Cancer Institute ; Division of Cancer Epidemiology and Genetics, National Cancer Instituteen_US
dc.language.isoengen_US
dc.publisherBioMed Central Ltden_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.rightsAttribution 4.0 International*
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/*
dc.subjectBreast Canceren_US
dc.subjectCoronavirus Pandemicen_US
dc.subjectCOVID-19en_US
dc.subjectHealth Care Utilizationen_US
dc.titleAn examination of health care utilization during the COVID-19 pandemic among women with early-stage hormone receptor-positive breast canceren_US
dc.typearticleen_US
dc.relation.ispartofBMC Health Services Researchen_US
dc.departmentİstanbul Medipol Üniversitesi, Tıp Fakültesi, Temel Tıp Bilimleri Bölümü, Biyoistatistik ve Tıp Bilişimi Ana Bilim Dalıen_US
dc.authorid0000-0002-3386-1734en_US
dc.identifier.volume22en_US
dc.identifier.issue1en_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.identifier.doi10.1186/s12913-022-08705-9en_US
dc.institutionauthorKoçak, Mehmet
dc.identifier.wosqualityQ3en_US
dc.identifier.wos000886973900003en_US
dc.identifier.scopus2-s2.0-85142441375en_US
dc.identifier.pmid36419005en_US
dc.identifier.scopusqualityQ1en_US


Bu öğenin dosyaları:

Thumbnail

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster

info:eu-repo/semantics/openAccess
Aksi belirtilmediği sürece bu öğenin lisansı: info:eu-repo/semantics/openAccess